当前位置: 首页 >> 检索结果
321. Linear extrapolation of missing radiographic change scores in clinical trials does not spuriously overestimate group radiographic changes in rheumatoid arthritis.
作者: Iris M Markusse.;Robert Landewé.;Ron Wolterbeek.;Meilien Ho.;Martin Jenkins.;Désirée van der Heijde.
来源: Rheumatology (Oxford). 2016年55卷7期1295-300页
To assess linear extrapolation (LE) and last observation carried forward (LOCF) as imputation methods for radiographic change in patients with RA.
322. Muscles in motion: a randomized controlled trial on the feasibility, safety and efficacy of an exercise training programme in children and adolescents with juvenile dermatomyositis.
作者: G Esther A Habers.;G J F Joyce Bos.;Annet van Royen-Kerkhof.;Otto T H M Lelieveld.;Wineke Armbrust.;Tim Takken.;Marco van Brussel.
来源: Rheumatology (Oxford). 2016年55卷7期1251-62页
To study for the first time in a randomized controlled trial the feasibility, safety and efficacy of an exercise training programme in children and adolescents with JDM.
323. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis.
作者: Vibeke Strand.;Ronald F van Vollenhoven.;Eun Bong Lee.;Roy Fleischmann.;Samuel H Zwillich.;David Gruben.;Tamas Koncz.;Bethanie Wilkinson.;Gene Wallenstein.
来源: Rheumatology (Oxford). 2016年55卷6期1031-41页
To evaluate effects of tofacitinib or adalimumab on patient-reported outcomes (PROs) in patients with moderate to severe RA and inadequate responses to MTX.
324. Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab.
作者: Rohit Aggarwal.;Chester V Oddis.;Danielle Goudeau.;Diane Koontz.;Zengbiao Qi.;Ann M Reed.;Dana P Ascherman.;Marc C Levesque.
来源: Rheumatology (Oxford). 2016年55卷6期991-9页
To determine the longitudinal trends in serum levels of four myositis-associated autoantibodies: anti-Jo-1, -transcription intermediary factor 1 γ (TIF1-γ), -signal recognition particle (SRP) and -Mi-2, after B cell depletion with rituximab, and to determine the longitudinal association of these autoantibody levels with disease activity as measured by myositis core-set measures (CSMs).
325. Content validity of global measures for at-work productivity in patients with rheumatic diseases: an international qualitative study.
作者: Sarah Leggett.;Antje van der Zee-Neuen.;Annelies Boonen.;Dorcas Beaton.;Mihai Bojinca.;Ailsa Bosworth.;Sabrina Dadoun.;Bruno Fautrel.;Sofia Hagel.;Catherine Hofstetter.;Diane Lacaille.;Denise Linton.;Carina Mihai.;Ingemar F Petersson.;Pam Rogers.;Carlo Sciré.;Suzanne M M Verstappen.; .
来源: Rheumatology (Oxford). 2016年55卷8期1364-73页
To identify from a patient's perspective, difficulties and differences in the comprehension of five global presenteeism measures in patients with inflammatory arthritis and OA across seven countries.
326. Pulsed electromagnetic fields in knee osteoarthritis: a double blind, placebo-controlled, randomized clinical trial.
作者: Gian Luca Bagnato.;Giovanni Miceli.;Natale Marino.;Davide Sciortino.;Gian Filippo Bagnato.
来源: Rheumatology (Oxford). 2016年55卷4期755-62页
This trial aimed to test the effectiveness of a wearable pulsed electromagnetic fields (PEMF) device in the management of pain in knee OA patients.
327. Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritis.
作者: Edward C Keystone.;Janet E Pope.;J Carter Thorne.;Melanie Poulin-Costello.;Krystene Phan-Chronis.;Andrew Vieira.;Boulos Haraoui.; .
来源: Rheumatology (Oxford). 2016年55卷2期327-34页
To evaluate radiographic and clinical outcomes up to 24 months in patients with RA enrolled in the Canadian Methotrexate and Etanercept Outcome study.
328. Autologous adipose-derived stromal vascular fraction in patients with systemic sclerosis: 12-month follow-up.
作者: Perrine Guillaume-Jugnot.;Aurélie Daumas.;Jérémy Magalon.;Elisabeth Jouve.;Pierre-Sébastien Nguyen.;Romain Truillet.;Stéphanie Mallet.;Dominique Casanova.;Laurent Giraudo.;Julie Veran.;Françoise Dignat-George.;Florence Sabatier.;Guy Magalon.;Brigitte Granel.
来源: Rheumatology (Oxford). 2016年55卷2期301-6页
Impaired hand function greatly contributes to disability and reduced quality of life in SSc patients. Autologous adipose-derived stromal vascular fraction (ADSVF) is recognized as an easily accessible source of regenerative cells. We reported positive 6-month safety and efficacy results from an open-label clinical trial assessing s.c. injection of autologous ADSVF into the fingers in SSc patients. The objective of this report is to describe the effects at 12 months.
329. Symptoms of depression and anxiety predict treatment response and long-term physical health outcomes in rheumatoid arthritis: secondary analysis of a randomized controlled trial.
作者: Faith Matcham.;Sam Norton.;David L Scott.;Sophia Steer.;Matthew Hotopf.
来源: Rheumatology (Oxford). 2016年55卷2期268-78页
The aim of this analysis is to examine the longitudinal impact of symptoms of depression/anxiety on treatment response, long-term disease activity and physical disability in RA.
330. Inefficacy of ultrasound-guided local injections of autologous conditioned plasma for recent epicondylitis: results of a double-blind placebo-controlled randomized clinical trial with one-year follow-up.
作者: Bernard Montalvan.;Patrick Le Goux.;Shahnaz Klouche.;Delphine Borgel.;Philippe Hardy.;Maxime Breban.
来源: Rheumatology (Oxford). 2016年55卷2期279-85页
The aim was to assess the efficacy of two intra-tendinous injections of platelet-rich plasma (PRP) on epicondylitis of recent evolution (≤3 months).
331. Elevated baseline power Doppler discriminates an RA subgroup highly responsive to therapy.
作者: Veena K Ranganath.;Ami Ben-Artzi.;Erin Duffy.;Jenny Brook.;Mihaela Taylor.;Soo Choi.;Harold Paulus.;David A Elashoff.
来源: Rheumatology (Oxford). 2015年54卷12期2285-6页 332. ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis.
作者: Désirée van der Heijde.;Avani Joshi.;Aileen L Pangan.;Naijun Chen.;Keith Betts.;Manish Mittal.;Yanjun Bao.
来源: Rheumatology (Oxford). 2016年55卷1期80-8页
To assess the impact of achieving Assessment in SpondyloArthritis international Society 40% (ASAS40) response or an Ankylosing Spondylitis Disease Activity Score inactive disease (ASDAS-ID) state on patient-reported outcomes (PROs) among patients with non-radiographic axial SpA (nr-axSpA).
333. Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis.
作者: Gerd R Burmester.;Patrick Durez.;Galina Shestakova.;Mark C Genovese.;Hendrik Schulze-Koops.;Yue Li.;Ying A Wang.;Steve Lewitzky.;Irina Koroleva.;Anni Agarwal Berneis.;David M Lee.;Wolfgang Hueber.
来源: Rheumatology (Oxford). 2016年55卷1期49-55页
To assess whether preliminary findings of associations between the HLA-DRB1*04 and HLA-DRB1* shared epitope (SE) allelic groups and response to the anti-IL-17A mAb secukinumab in RA were reproducible in an independent RA cohort.
334. Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: the BELISS open-label phase II study.
作者: Salvatore De Vita.;Luca Quartuccio.;Raphaèle Seror.;Sara Salvin.;Philippe Ravaud.;Martina Fabris.;Gaétane Nocturne.;Saviana Gandolfo.;Miriam Isola.;Xavier Mariette.
来源: Rheumatology (Oxford). 2015年54卷12期2249-56页
To report the efficacy and safety of long-term treatment of SS with belimumab, targeting the B-cell-activating factor.
335. Depressive symptoms predict future simple disease activity index scores and simple disease activity index remission in a prospective cohort of patients with early inflammatory polyarthritis.
作者: Charlotte Leblanc-Trudeau.;Patricia L Dobkin.;Nathalie Carrier.;Pierre Cossette.;Artur J de Brum-Fernandes.;Patrick Liang.;Ariel Masetto.;Gilles Boire.
来源: Rheumatology (Oxford). 2015年54卷12期2205-14页
To determine whether depressive symptoms assessed in treated patients with early inflammatory polyarthritis (EPA) influence disease activity during follow-up.
336. Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy.
作者: Daniel E Furst.;Arthur Kavanaugh.;Stefan Florentinus.;Hartmut Kupper.;Mahinda Karunaratne.;Charles A Birbara.
来源: Rheumatology (Oxford). 2015年54卷12期2188-97页
To evaluate the long-term effectiveness and safety of 10 years of adalimumab (ADA) treatment in DMARD-refractory RA patients and to analyse efficacy based on RF status and baseline disease duration.
337. The effect on treatment response of fibromyalgic symptoms in early rheumatoid arthritis patients: results from the ESPOIR cohort.
作者: Josefina Durán.;Bernard Combe.;Jingbo Niu.;Nathalie Rincheval.;Cécile Gaujoux-Viala.;David T Felson.
来源: Rheumatology (Oxford). 2015年54卷12期2166-70页
To evaluate whether patients with RA who belong to the spectrum of fibromyalgic RA (FRA) have an impaired response to treatment measured by traditional activity scores.
338. Intravenous neridronate in the treatment of acute painful knee osteoarthritis: a randomized controlled study.
作者: Massimo Varenna.;Francesca Zucchi.;Simonetta Failoni.;Andrea Becciolini.;Massimo Berruto.
来源: Rheumatology (Oxford). 2015年54卷10期1826-32页
The aim of this randomized, double-blind, placebo-controlled study was to assess the efficacy of i.v. neridronate in controlling pain in patients with acute painful knee OA.
339. Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy.
作者: Divi Cornec.;Valérie Devauchelle-Pensec.;Xavier Mariette.;Sandrine Jousse-Joulin.;Jean-Marie Berthelot.;Aleth Perdriger.;Xavier Puéchal.;Véronique Le Guern.;Jean Sibilia.;Jacques-Eric Gottenberg.;Laurent Chiche.;Eric Hachulla.;Pierre Yves Hatron.;Vincent Goeb.;Gilles Hayem.;Jacques Morel.;Charles Zarnitsky.;Jean Jacques Dubost.;Raphaèle Seror.;Jacques-Olivier Pers.;Petra M Meiners.;Arjan Vissink.;Hendrika Bootsma.;Emmanuel Nowak.;Alain Saraux.
来源: Rheumatology (Oxford). 2015年54卷9期1699-708页
To determine which outcome measures detected rituximab efficacy in the Tolerance and Efficacy of Rituximab in Sjögren's Disease (TEARS) trial and to create a composite endpoint for future trials in primary SS (pSS).
340. Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren's syndrome.
作者: Elena Pontarini.;Martina Fabris.;Luca Quartuccio.;Monica Cappeletti.;Francesca Calcaterra.;Alessandra Roberto.;Francesco Curcio.;Domenico Mavilio.;Silvia Della Bella.;Salvatore De Vita.
来源: Rheumatology (Oxford). 2015年54卷8期1429-34页
The aim of this study was to investigate the biological effects of belimumab on B cells in the first phase II open-label trial with belimumab in patients with primary SS (pSS) (BELISS).
|